Zykadia was 1st FDA win for Novartis in San Diego
This article was originally published in Scrip
Executive Summary
The Genomics Institute of the Novartis Research Foundation (GNF) in San Diego reached a major milestone in April with US FDA approval for the lung cancer drug Zykadia (ceritinib), because it was the first FDA approval for a compound discovered at GNF.
You may also be interested in...
Finance Watch: Scripps Research Models A New Way To Fund Translation
Private Company Edition: Scripps Research has a new model for translating academic findings into drugs, including a novel fund for financing that work. Also, in venture capital deals, Oyster Point closes a $93m Series B round and Peloton raises a $150m Series E.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.